Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06293326
Other study ID # 22553
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 6, 2024
Est. completion date June 6, 2024

Study information

Verified date May 2024
Source Bayer
Contact Bayer Clinical Trials Contact
Phone (+)1-888-84 22937
Email clinical-trials-contact@bayer.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers are looking for a better way to treat people who have heartburn, indigestion, and problems due to excessive stomach acid. These are common problems which can affect daily life and disturb sleep during the night-time. Heartburn is the burning sensation or pain in the chest which occurs when stomach acid rises up in the food pipe (esophagus). Calcium carbonate tablets are used to treat heartburn, indigestion, and related digestive problems. Calcium carbonate works by neutralizing the excess acid in the stomach. The study treatment is a new bi-layer calcium carbonate tablet that has two layers. One layer quickly releases calcium carbonate aimed to provide quick relief (called immediate release) while the other layer releases calcium carbonate slowly to make the relief last longer (called sustained release). In this study, bi-layer calcium carbonate tablets will be given to healthy men for the first time. This study will provide information on how the new bi-layer tablet works inside the body. The main purpose of this study is to learn about how the new bi-layer calcium carbonate tablet changes the average acidity levels (measured using pH) compared to the standard calcium carbonate tablet during the night-time. For this, researchers will measure the acidity levels in the upper part of the stomach at regular intervals during the night-time. The participants will be randomly (by chance) assigned to one of two treatment groups: Participants in the first group will take the treatments at night. Participants in the second group will take the treatments during the day. All participants in both groups will take 2 bi-layer tablets and 2 standard tablets after a meal with a gap of 6 to 8 days between treatments. However, in each group, half the participants will receive the bi-layer tablets first while the other half will receive the standard tablets first. Each participant will be in the study for around 52 days with up to 4 visits to the study site. This includes: 1. visit about 28 days before the treatment starts during which the doctors will confirm that the participant can take part in the study 2. visits for treatment with a gap of 6-8 days between each treatment, and 1 visit 7 to 14 days after the treatment ends during which the doctors will monitor the participants' health. During the study, the doctors and their study team will: check participants' overall health by performing tests such as blood and urine tests, and check heart health using an electrocardiogram (ECG) take images of the stomach at different times after taking the treatment measure acidity level (pH) using a device called pH probe that is inserted into the upper part of the stomach ask the participants questions about how easy it is to take the study treatment ask the participants what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think it is related to the study treatment, or not. As this study is conducted in healthy men who will not gain any benefit from this treatment, access to the study treatment after the study is not planned.


Recruitment information / eligibility

Status Recruiting
Enrollment 16
Est. completion date June 6, 2024
Est. primary completion date June 6, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Male - Participant must be 18 to =65 years of age inclusive, at the time of signing the informed consent. - Participants must have a verified diagnosis of "healthy": the results of the standard clinical, laboratory, and instrumental examinations are within the normal range (limits of reference range). The Investigator can interpret individual findings based on the participant's age, physical state and level of fitness. Participants with readings marginally outside the normal range may be included in the study if, in the Investigator's opinion, these are not clinically significant (NCS); this decision will be documented in the Case Report Form (CRF). - Results of safety laboratory tests are within normal range (limits of reference range). - Non-smokers or passive smokers exposed to smoke in an enclosed room for less than 4 h per week. - Body mass index (BMI) within the range 18.5 to =30 kg/m2 (inclusive). - Unless participant has had bilateral orchidectomy or a vasectomy (with confirmed sterility), must be abstinent from penile-vaginal intercourse for the duration of the study and agree to remain abstinent for 90 days after the last dose of IMP, OR agree to use a condom during each episode of penile-vaginal intercourse, in addition to their partner (if a person who could become pregnant) using a highly effective form of contraception as described in protocol. - Participant has given written informed consent to participate in the trial prior to admission to the trial as described in the protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. - Be willing and able to participate in all scheduled visits, treatment plan, laboratory tests and other trial procedures according to the protocol. Exclusion Criteria: - A history of physical or psychiatric diseases (e.g., diabetes, hypothyroidism and other metabolic diseases, renal disease). - Recent unexplained significant weight loss (6-7 kg) in the last 6 months. - A history or current symptoms of Zollinger-Ellison syndrome, gastric carcinoma, peptic ulcer disease, pernicious anaemia, Barrett's oesophagus or systemic sclerosis. - Meal-induced heartburn of severe severity, historically and - - Use of any H2-receptor antagonist and/or PPI within one week prior to Screening. - History and currently prescribed medication for treatment of heartburn associated with increased acidity, reflux esophagitis, and peptic ulcers. - Current or history of drug or alcohol abuse.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
bi-layer calcium carbonate tablet (BAY1180654)
Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
Immediate release calcium carbonate tablet (BAY1180654)
Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.

Locations

Country Name City State
United Kingdom BDD Pharma Bio-imaging Unit Glasgow

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gastric pH levels as measured and recorded with tip of pH probe in gastric fundus. During night-time on Day 1
Secondary Gastric pH levels as measured and recorded with tip of pH probe in gastric fundus. During daytime on Day 1
Secondary Percentage of total time gastric pH is above pH 3.5 from time of dosing until 8h post-dose during night-time comparing the bi-layer tablet and standard comparator Up to 8 hours post-dose during night-time
Secondary Percentage of total time gastric pH is above pH 3.5 from time of dosing until 6h post-dose during daytime comparing the bi-layer tablet and standard comparator. Up to 6 hours post-dose during daytime
Secondary Change in mean gastric pH During night-time and daytime on Day 1
Secondary Gastrointestinal tract location using scintigraphic images. During night-time and daytime on Day 1
Secondary Initial radiolabel release time, using scintigraphic images During night-time and daytime on Day 1
Secondary Disintegration rate (t50%) of each formulation will be determined quantitatively via analysis of scintigraphic images. During night-time and daytime on Day 1
Secondary Complete radiolabel release time, using scintigraphic images During night-time and daytime on Day 1
Secondary Gastric emptying kinetics of the dispersed radiolabeled material (t50% and t90%) of each formulation will be determined quantitatively via analysis of the scintigraphic images. During night-time and daytime on Day 1
Secondary Participant questionnaire The following questions will be asked:
PERCEPTIONS Focusing on the sensory experience you have had from the tablet; please indicate how much you agree/disagree with each of the following statements?
This tablet feels like is easy to swallow
This tablet is pleasant to use
On Day 1
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1